PDCD1 and non-small cell lung carcinoma: Together, these findings indicate that dual PD-1 and CTLA-4 blockade holds promise for overcoming ICI resistance in NSCLC, while underscoring the need to differentiate primary from acquired resistance and to develop mutation-specific combination strategies.